Competitive Generic Therapy Designations Growing Despite Lack Of Guidance
Executive Summary
US FDA developing document describing program operations, but that has not stopped sponsors from requesting and receiving the breakthrough-like designation.
You may also be interested in...
Let's Get Real – ANDA Approval Likely Takes More Than Two Years, US FDA Says
Office of Generic Drugs Director Kathleen Uhl calls a two-cycle approval timeline a realistic expectation for ANDA approval, but would not say that most ANDAs will fall into the paradigm.
New ANDA Review Pathways: Should You Be A Priority Or Expedited?
Amid confusion about multiple priority and expedited pathways for US generic drug applications, industry asks which are a true advantage.
Breakthrough-Style Program For ANDAs Added To House User Fee Bill
Energy and Commerce subcommittee unanimously advances reauthorization legislation with four added amendments, including one that would allow for certain generic sponsors to meet early and often with FDA to speed development.